Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

143.18
+2.471.76%
Post-market: 142.40-0.7800-0.54%19:30 EDT
Volume:1.65M
Turnover:235.71M
Market Cap:14.60B
PE:20.98
High:144.56
Open:141.41
Low:140.36
Close:140.71
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.03
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.95
PE(LYR):30.66

Loading ...

Neurocrine Biosciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Neurocrine Biosciences, Inc : Baird Raises Target Price to $225 from $186

THOMSON REUTERS
·
Jul 31

Neurocrine Director Leslie V. Norwalk Sells 1,250 Shares for $227,507.5

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS USD 2.85 Vs. IBES Estimate USD 1.34

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate

Benzinga Earnings
·
Jul 31

Neurocrine Biosciences, Inc: Ingrezza(Valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion

THOMSON REUTERS
·
Jul 31

Neurocrine Biosciences Q2 Product Sales USD 954.3 Million

THOMSON REUTERS
·
Jul 31

Neurocrine Biosciences Q2 EPS USD 1.39

THOMSON REUTERS
·
Jul 31

Jefferies Keeps Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Jul 30

Earning Preview: Neurocrine Biosciences this quarter’s revenue is expected to increase by 34.84%, and institutional views are bullish

Earnings Agent
·
Jul 24

Neurocrine Names Bret Paulson Senior Vice President of Market Access

Reuters
·
Jul 24

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

THOMSON REUTERS
·
Jul 24

Neurocrine Appoints Samir Siddhanti as Chief Business Officer

Reuters
·
Jul 22

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

THOMSON REUTERS
·
Jul 22

Neurocrine is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price

Simply Wall St.
·
Jul 20

Neurocrine Biosciences, Inc. : Wells Fargo Raises Target Price to $200 from $175

THOMSON REUTERS
·
Jul 17

Wells Fargo Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
Jul 17

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Common Stock Sale Worth $1.8 Million

Reuters
·
Jul 14